The role of oncogenes in gastrointestinal cancer.

Oncogene research over the last century has been one of the major advances in understanding the molecular biology of malignant disease. Oncogenes are a structurally and functionally heterogeneous group of genes, whose protein products act pleiotropically and affect multiple complex regulatory cascades within the cell. They regulate cell proliferation, growth, and differentiation, as well as control of the cell cycle and apoptosis. The products of oncogenes include growth factors, growth factor receptors, signal transducers, transcription factors, and apoptosis regulators, as well as chromatin remodelers. Several distinct mechanisms have been described for the conversion of proto-oncogenes to active oncogenes. Quantitative forms of oncogene activation include multiplication (gene amplification) or translocation to an active chromatin domain that brings a growth-regulatory gene under the control of a different promoter, causing inappropriate expression of the gene. Qualitative forms include either point mutations or the production of a novel product from a chimeric gene. Further understanding of the molecular mechanisms by which oncogenes regulate normal development and tumorigenesis may lead to novel concepts in the diagnosis and treatment of cancer in humans. In this review, we focus on the role of selected oncogenes in gastrointestinal cancer.

[1]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[2]  Hansjuerg Alder,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[3]  L. Mazzucchelli,et al.  Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.

[4]  A. D. Van den Abbeele,et al.  Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure , 2009, Clinical Cancer Research.

[5]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[6]  Shuji Ogino,et al.  A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases , 2009, Clinical Cancer Research.

[7]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Liping Ying A Randomized Phase IIIB Trial of Chemotherapy,Bevacizumab,and Panitumumab Compared with Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer , 2009 .

[11]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Ogino,et al.  Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype , 2008, Histopathology.

[14]  H. Brenner,et al.  Stool testing for the early detection of pancreatic cancer: rationale and current evidence , 2008, Expert review of molecular diagnostics.

[15]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[16]  P. Assumpção,et al.  MYC and gastric adenocarcinoma carcinogenesis. , 2008, World journal of gastroenterology.

[17]  D. Sargent,et al.  Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.

[18]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[19]  K. Hunt,et al.  Genetic aberrations of gastrointestinal stromal tumors , 2008, Cancer.

[20]  X. Shu,et al.  Effect of Helicobacter pylori eradication on oncogenes and cell proliferation , 2008, European journal of clinical investigation.

[21]  L. Neckers,et al.  KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. , 2008, Leukemia research.

[22]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[23]  C. Antonescu,et al.  Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases , 2008, Modern Pathology.

[24]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[25]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Koopman,et al.  A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[28]  P. Jares,et al.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.

[29]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[30]  Safdar Ali,et al.  Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). , 2007, Gene.

[31]  Jun Kato,et al.  Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features , 2007, British Journal of Cancer.

[32]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[33]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[34]  R. Gurski,et al.  c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. , 2007, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[35]  M. Imoto,et al.  Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression , 2007, Cancer science.

[36]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[37]  K. M. Woods Ignatoski,et al.  Why should we still care about oncogenes? , 2007, Molecular Cancer Therapeutics.

[38]  Reuven Agami,et al.  Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. , 2007, The EMBO journal.

[39]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[40]  M. Sarbia,et al.  c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression. , 2006, Neoplasia.

[41]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[42]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[43]  Wei-Yu Tang,et al.  Gene-expression profiles in gastric epithelial cells stimulated with spiral and coccoid Helicobacter pylori. , 2006, Journal of medical microbiology.

[44]  R. Langer,et al.  Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study , 2006, Journal of Clinical Pathology.

[45]  Sarah Edkins,et al.  Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.

[46]  A. Godwin,et al.  Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. , 2006, Cancer research.

[47]  J. Lasota,et al.  KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). , 2006, Seminars in diagnostic pathology.

[48]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[49]  N. Iizuka,et al.  Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus , 2006, Journal of Cancer Research and Clinical Oncology.

[50]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.

[51]  A. Ristimäki,et al.  Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers , 2006, Modern Pathology.

[52]  A. Jimeno,et al.  Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[53]  W. Willett,et al.  Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma , 2006, British Journal of Cancer.

[54]  R. Shiekhattar,et al.  MicroRNA biogenesis: isolation and characterization of the microprocessor complex. , 2006, Methods in molecular biology.

[55]  S. Moss,et al.  Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis , 2006, Modern Pathology.

[56]  Chung-Ping Hsu,et al.  Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. , 2005, World journal of gastroenterology.

[57]  A. Rustgi,et al.  Mutant KRAS in the initiation of pancreatic cancer. , 2005, Biochimica et biophysica acta.

[58]  G. Pasz-Walczak,et al.  Cyclin D1 protein and CCND1 gene expression in colorectal cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[59]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Markku Miettinen,et al.  KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[61]  M. van Glabbeke,et al.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Evans,et al.  Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma , 2005, Cancer.

[63]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  A. Jubb,et al.  Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.

[65]  G. Sauter,et al.  Patterns of gene amplification in gastrointestinal stromal tumors (GIST) , 2005, Laboratory Investigation.

[66]  S. Kondo,et al.  Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. , 2005, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[67]  Jing-Yuan Fang,et al.  The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.

[68]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[69]  K. Araki,et al.  STI571 (Glivec) inhibits the interaction between c‐KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST‐T1 , 2005, Cancer science.

[70]  J. Kononen,et al.  Prevalence of KIT expression in human tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  I. Ng,et al.  High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. , 2004, Human pathology.

[72]  M. Feitelson c-myc overexpression in hepatocarcinogenesis. , 2004, Human pathology.

[73]  Geng-yin Zhou,et al.  Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance. , 2004, World journal of gastroenterology.

[74]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[75]  A. Bahnassy,et al.  Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients , 2004, BMC gastroenterology.

[76]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[77]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[78]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[79]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[80]  R. Brand,et al.  Reproducibility of a Multitarget Stool-Based DNA Assay for Colorectal Cancer Detection , 2004, American Journal of Gastroenterology.

[81]  P. Radice,et al.  Different Genetic Features Associated with Colon and Rectal Carcinogenesis , 2004, Clinical Cancer Research.

[82]  J. Cigudosa,et al.  Molecular alterations associated with cyclin d1 overexpression in endometrial cancer , 2004, International journal of cancer.

[83]  F. Herrmann,et al.  Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression , 2004, Cancer.

[84]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[85]  Masahiro Ito,et al.  Cyclin D1 overexpression in thyroid tumours from a radio‐contaminated area and its correlation with Pin1 and aberrant β‐catenin expression , 2004, The Journal of pathology.

[86]  J. Fletcher Role of KIT and platelet-derived growth factor receptors as oncoproteins. , 2004, Seminars in oncology.

[87]  M. van Glabbeke,et al.  Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.

[88]  Huan-Xing Yang,et al.  Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. , 2004, World journal of gastroenterology.

[89]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[90]  M. Seto,et al.  Cyclin D1 Expression Is Useful as a Prognostic Indicator for Advanced Esophageal Carcinomas, but Not for Superficial Tumors , 2000, Digestive Diseases and Sciences.

[91]  Gui-FangYang,et al.  Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: Association with Helicobactor pylori cagA (+) infection , 2004 .

[92]  Chenguang Wang,et al.  Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. , 2004, Cancer treatment and research.

[93]  L. Le Marchand,et al.  Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. , 2003, JAMA.

[94]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  R. Schneider-Stock,et al.  KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. , 2003, Human pathology.

[96]  H. Bidd,et al.  Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. , 2003, Human pathology.

[97]  Andrew J. Wilson,et al.  c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis , 2003, British Journal of Cancer.

[98]  D. Beer,et al.  Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  E. Wardelmann,et al.  Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.

[100]  R. Hruban,et al.  BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. , 2003, The American journal of pathology.

[101]  Andrea Tannapfel,et al.  Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays , 2003, The Journal of pathology.

[102]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[103]  D. Amadori,et al.  Fecal multiple molecular tests to detect colorectal cancer in stool. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[104]  M. Ladanyi,et al.  Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  G. Kuang,et al.  Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population , 2003, International journal of cancer.

[106]  M. Lawson,et al.  Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. , 2003, Clinical colorectal cancer.

[107]  Avijit Chakrabartty,et al.  Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.

[108]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[109]  B. Iacopetta,et al.  Prognostic Significance of Microsatellite Instability and Ki-ras Mutation Type in Stage II Colorectal Cancer , 2003, Oncology.

[110]  R. Goldbohm,et al.  K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.

[111]  B. Klump,et al.  C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality. , 2003, Anticancer research.

[112]  B. C. Wong,et al.  Effect of Helicobacter pylori on apoptosis and apoptosis related genes in gastric cancer cells , 2003, Molecular pathology : MP.

[113]  D. Wakelin,et al.  Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.

[114]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[115]  X. Guan,et al.  Prognostic significance of c‐myc and AIB1 amplification in hepatocellular carcinoma , 2002, Cancer.

[116]  Tony Pawson,et al.  Regulation and targets of receptor tyrosine kinases. , 2002, European journal of cancer.

[117]  T. Aoki,et al.  Cell cycle-regulated factors in esophageal cancer. , 2002, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[118]  G. Demetri Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). , 2002, European journal of cancer.

[119]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[120]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[121]  O. Delpuech,et al.  Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma , 2002, Oncogene.

[122]  Y. Nakagawa,et al.  A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[123]  E. Wardelmann,et al.  c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant , 2002, Modern Pathology.

[124]  J. Shimazaki,et al.  Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[125]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[126]  T. Takayama,et al.  Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. , 2001, Gastroenterology.

[127]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[128]  Y. Shyr,et al.  Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. , 2001, Cancer research.

[129]  A. Pasquinelli,et al.  A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA , 2001, Science.

[130]  A. Xu,et al.  Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. , 2001, World journal of gastroenterology.

[131]  P. Catalano,et al.  c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. , 2001, Cancer research.

[132]  M. Wolter,et al.  Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. , 2001, American journal of clinical pathology.

[133]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[134]  T. Nishida,et al.  Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.

[135]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[136]  J. Aster,et al.  Molecular biology of Burkitt's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  S. Thibodeau,et al.  Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. , 2000, Gastroenterology.

[138]  M. Leppert,et al.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[139]  J. McKay,et al.  Cyclin D1 protein expression and gene polymorphism in colorectal cancer , 2000, International journal of cancer.

[140]  D. Forman,et al.  Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[141]  I. Weinstein Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. , 2000, Carcinogenesis.

[142]  E. de Álava,et al.  Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins , 2000, International journal of surgical pathology.

[143]  S. Hammond,et al.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.

[144]  K. Klempnauer,et al.  Regulation of B-Myb activity by cyclin D1 , 2000, Oncogene.

[145]  R Mera,et al.  Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. , 2000, Human pathology.

[146]  G. Capellá,et al.  A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. , 2000, International journal of cancer.

[147]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[148]  Y. Takano,et al.  Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis , 1999, The Journal of pathology.

[149]  G. Hommel,et al.  Expression of cell‐cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer , 1999, The Journal of pathology.

[150]  M. Wolter,et al.  Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. , 1999, The American journal of pathology.

[151]  M. S. Lee,et al.  c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. , 1999, Journal of Korean medical science.

[152]  Y. Morishita,et al.  Amplification of c-myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overexpression , 1999, Oncology.

[153]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[154]  M. Schwab Oncogene amplification in solid tumors. , 1999, Seminars in cancer biology.

[155]  J. Segall,et al.  The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. , 1999, Endocrine reviews.

[156]  M. Monden,et al.  Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.

[157]  S. Goodman,et al.  Genetic epidemiology of mutated K-rasproto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas , 1999, Gut.

[158]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[159]  L. Regan,et al.  Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.

[160]  Q. Wei,et al.  Coupling of the cell cycle and myogenesis through the cyclin D1‐dependent interaction of MyoD with cdk4 , 1999, The EMBO journal.

[161]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[162]  H. Hsu,et al.  Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. , 1998, Journal of hepatology.

[163]  M. Schwab Amplification of oncogenes in human cancer cells , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[164]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[165]  S. Kitano,et al.  Prognostic significance of c-myc mRNA expression assessed by semi-quantitative RT-PCR in patients with colorectal cancer. , 1998, Oncology reports.

[166]  C. Sherr,et al.  Gene Expression and Cell Cycle Arrest Mediated by Transcription Factor DMP1 Is Antagonized by D-Type Cyclins through a Cyclin-Dependent-Kinase-Independent Mechanism , 1998, Molecular and Cellular Biology.

[167]  D. Schiffer,et al.  Cyclin D1 expression in gliomas , 1998, Acta Neuropathologica.

[168]  K. Maeda,et al.  Cyclin D1 Overexpression and Prognosis in Colorectal Adenocarcinoma , 1998, Oncology.

[169]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[170]  M. Imamura,et al.  Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. , 1997, Annals of surgery.

[171]  P. Chikhlikar,et al.  Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma , 1997, Diseases of the colon and rectum.

[172]  K. Maeda,et al.  Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma , 1997, International journal of cancer.

[173]  G. Corner,et al.  Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. , 1997, Cancer research.

[174]  R. Herrmann,et al.  Overexpression and amplification of c-myc during progression of human colorectal cancer. , 1996, Oncology.

[175]  M. Kitajima,et al.  Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[176]  Y. Kohata [Detection of K-ras point mutations in the stool of patients with colorectal tumors]. , 1996, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[177]  A. Neugut,et al.  Increased expression of the cyclin D1 gene in Barrett's esophagus. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[178]  C. Wagener,et al.  Detection of K‐ras mutations in stools of patients with colorectal cancer by mutant‐enriched PCR , 1996, International journal of cancer.

[179]  A. Rebecchi,et al.  Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. , 1996, Gastroenterology.

[180]  T. Kanematsu,et al.  Mutations of the p53 gene in the stool of patients with resectable colorectal cancer , 1996, Cancer.

[181]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[182]  T. Gansler,et al.  c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[183]  G. Peters,et al.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.

[184]  Y. Chung,et al.  Overexpression of c-myc messenger RNA in primary and metastatic lesions of carcinoma of the stomach. , 1996, Journal of the American College of Surgeons.

[185]  M. Ogawa,et al.  Ethnic difference in the pattern of K‐ras oncogene mutations in human colorectal cancers , 1996, Human mutation.

[186]  N Thatcher,et al.  Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.

[187]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[188]  T. Hattori,et al.  Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. , 1995, The American journal of pathology.

[189]  H. Ohta,et al.  Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). , 1995, Oncogene.

[190]  H. Esumi,et al.  Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. , 1995, Gastroenterology.

[191]  M. Eisenstein,et al.  The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction , 1995, Cell.

[192]  W. Bodmer,et al.  Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. , 1995, Gut.

[193]  D. Klimstra,et al.  K-ras mutations in pancreatic ductal proliferative lesions. , 1994, The American journal of pathology.

[194]  C. Sherr G1 phase progression: Cycling on cue , 1994, Cell.

[195]  J. Bartek,et al.  The PRAD‐1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas , 1994, International journal of cancer.

[196]  R. Hruban,et al.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.

[197]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[198]  T. Saito,et al.  c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. , 1994, European journal of cancer.

[199]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[200]  H. Kim,et al.  Expression of cellular oncogenes in human gastric carcinoma: c‐myc, c–erb B2′ and c‐Ha‐ras , 1993, Journal of surgical oncology.

[201]  C. J. Chen,et al.  Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.

[202]  C. Harris,et al.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[203]  H. Hsu,et al.  Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. , 1993, Journal of the Formosan Medical Association = Taiwan yi zhi.

[204]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[205]  S. Lev,et al.  Structure‐function analyses of the kit receptor for the steel factor , 1993, Stem cells.

[206]  H. Saisho,et al.  Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. , 1993, Cancer research.

[207]  P. Quirke,et al.  p53 expression and K-ras mutation in colorectal adenomas. , 1993, Gut.

[208]  S. Nishikawa,et al.  Interspecies molecular chimeras of kit help define the binding site of the stem cell factor , 1993, Molecular and cellular biology.

[209]  K. Stȩpniewska,et al.  High frequency of K-ras mutations in sporadic colorectal adenomas. , 1993, Gut.

[210]  M. Brizzi,et al.  Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. , 1993, The Journal of biological chemistry.

[211]  Bruno Amati,et al.  Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.

[212]  R. Eisenman,et al.  Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.

[213]  I. Weinstein,et al.  Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.

[214]  G. Fourel,et al.  Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[215]  R. Eisenman,et al.  Myc and Max function as a nucleoprotein complex , 1992, Current Biology.

[216]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[217]  L. Pavelic,et al.  High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. , 1992, Anticancer research.

[218]  N. Harris,et al.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[219]  A. Arnold,et al.  A novel cyclin encoded by a bcl1-linked candidate oncogene , 1991, Nature.

[220]  J. Bishop Molecular themes in oncogenesis , 1991, Cell.

[221]  Frank McCormick,et al.  The GTPase superfamily: conserved structure and molecular mechanism , 1991, Nature.

[222]  L. Augenlicht,et al.  Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. , 1991, Oncogene.

[223]  H. Shiku,et al.  Expression of c-myc gene product in gastric carcinoma. , 1991, Oncology.

[224]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[225]  M. Meldrum,et al.  Nobel Laureates in Medicine or Physiology , 1990 .

[226]  A. Pardee G1 events and regulation of cell proliferation. , 1989, Science.

[227]  G. Stenman,et al.  Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene , 1989, Genes, chromosomes & cancer.

[228]  P. Newmark Nobel for oncogenes , 1989, Nature.

[229]  A. Look,et al.  Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes , 1988, Cell.

[230]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[231]  G. Fleuren,et al.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.

[232]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[233]  S. Litwin,et al.  Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. , 1988, Cancer Research.

[234]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[235]  B. Wilson,et al.  Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis. , 1987, Journal of clinical pathology.

[236]  J. Costa,et al.  Prognostic implications of expression of the cellular genes myc, fos, Ha‐ras and Ki‐ras in colon carcinoma , 1987, International journal of cancer.

[237]  K. Sikora,et al.  c‐myc oncogene expression in colorectal cancer , 1987, Cancer.

[238]  F. Alt,et al.  Myc family of cellular oncogenes , 1987, Journal of cellular biochemistry.

[239]  William E. Grizzle,et al.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis , 1987, Nature.

[240]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.

[241]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[242]  J. Yokota,et al.  Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. , 1986, Science.

[243]  J. Stewart,et al.  Detection of the c-myc oncogene product in colonic polyps and carcinomas. , 1986, British Journal of Cancer.

[244]  M. Erisman,et al.  Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene , 1985, Molecular and cellular biology.

[245]  R. Weinberg,et al.  Cellular oncogenes and multistep carcinogenesis. , 1983, Science.

[246]  P. Leder,et al.  The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphoma , 1983, Cell.

[247]  P. Rothberg,et al.  Oncogenes and cancer. , 1983, Cancer investigation.

[248]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[249]  R. Weinberg,et al.  Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene , 1982, Nature.

[250]  B. Vennstrom,et al.  Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29 , 1982, Journal of virology.

[251]  J. Bishop Retroviruses and cancer genes. , 1982, Advances in cancer research.

[252]  J. Bishop,et al.  Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29 , 1978, Journal of virology.

[253]  H. Varmus,et al.  DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA , 1976, Nature.

[254]  P. Vogt,et al.  Differences between the Ribonucleic Acids of Transforming and Nontransforming Avian Tumor Viruses* , 1970, Proceedings of the National Academy of Sciences.

[255]  H. Temin,et al.  Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. , 1958, Virology.

[256]  P. Rous A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS , 1911, The Journal of experimental medicine.

[257]  P. Rous,et al.  A TRANSMISSIBLE AVIAN NEOPLASM. (SARCOMA OF THE COMMON FOWL.) , 1910, The Journal of experimental medicine.